Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind placebo-controlled phase 2 study of PPM-204 in type 2 diabetes
2006-003897-87Phase 2Completed
- Sponsor
- Wyeth
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Indeglitazar in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Wyeth. Primary endpoint: Change from baseline to Week 12 in fasting plasma glucose. Started Dec 2006; status: completed.
02
Drugs
Indeglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-003897-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003897-87.